Original Research

68. Blood glucose levels should be considered as a new vital sign indicative of prognosis during hospitalization.Kesavadev J, Misra A, Saboo B, Aravind SR, Hussain A, Czupryniak L, Raz I. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. January–February 2021: 221-227. Link 1 | Link 2
67. Time-in-range as a target in type 2 diabetes: An urgent need.Saboo B, Kesavadev J, Shankar. A, Krishna M.B, Sheth S, Patel V, Krishnan G. Heliyon. Vol 7(3). Jan 2021: e05967. Read More
66. Understanding Patients’ Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market.Murthy S, Aneja P, Asirvatham A.J, Husemoen L.L, Rhee N.A, Kesavadev J. Pharmaco Economics-Open, Jan 2021:1-3. Read More
65. The SAGE Study: Global Observational Analysis Of Glycaemic Control, Hypoglycaemia And Diabetes Management In T1DM.Renard E, Ikegami H, Daher Vianna AG, Pozzilli P, Brette S, Bosnyak Z, Lauand F, Peters A, Pilorget V, Jurišić-Eržen D, Kesavadev J, Seufert J, Wilmot EG. Diabetes/Metabolism Research and Reviews. 2020 Dec 28. Read More
64. Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel.Chawla M, Jain SM, Kesavadev J, Makkar BM, Viswanathan V, Tiwaskar M, Sosale AR, Negalur V, Modi KD, Gupta M, Kumar S, Ramakrishnan S, Deka N, Roy N. Diabetes Ther. 2020 Dec 12:1–10. doi: 10.1007/s13300-020-00979-8. Read More
63. Management of children and adolescents having type 1 diabetes during COVID-19 pandemic in India: challenges and solutions.Jethwani P, Saboo B, Jethwani L, Kesavadev J, Kalra S, Sahay R, Agarwal S, Hasnani D. International Journal of Diabetes in Developing Countries. 2020 Sep;40(3):335-9. Read More
62. Association of nutritional status with dietary and behavioural patterns among adolescents.Elizabeth KE, Ashok AD, Kesavadev J. Int J Contemp Pediatr. 2020 Sep;7(9):1918-1922. Read More
61. A 2020 Update On Diabetes Technologies With Emphasis On Telemedicine During COVID-19.Kesavadev J. Kerala Medical Journal. Vol 12: issue 3;Jul- Sept 2020: 112-115. Read More
60. Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas.Kesavadev J, Saboo B, Krishna M.B, Krishnan G. Diabetes Ther. Jun 2020;10.1007/s13300-020-00831-z. Read More
59. Diabetes and coronavirus disease-2019 (COVID-19).Unnikrishnan R, Saboo B, Kesavadev J, Deshpande N, Ramachandra Aravind S. R, Joshi S, Anjana R. M, Hussain A, Mohan V. J Diabetol. Jun 2020;11:52-6. Read More
58. Harnessing the Possibilities of Telemedicine for Consultations in COVID Crisis.Kesavadev J. Int J Diab May 2020;1-6. Read More
57. The Do-It-Yourself Artificial Pancreas: A Comprehensive Review.Kesavadev J, Srinivasan S, Saboo B, Krishna M. B, Krishnan G. Diabetes Ther. Apr 2020. Read More
56. Real-world Data Reveal Unmet Clinical Needs in Insulin Treatment in Asian People With Type 2 Diabetes: The Joint Asia Diabetes Evaluation (JADE) Register.Kong A. P. S, Lew T, Lau E. S. H, Lim L. L, Kesavadev J, Jia W, Sheu W H-H, Sobrepena L, Tan A. T. B, Nguyen T. K, Yoon K. H, Wang K, Kodiappan K, Treuer T, Chan J. C. N, JADE Collaborative Study Group. Diabetes Obes Metab.Apr 2020;22(4):669-679. Link 1 | Link 2 | Link 3
55. Consensus and recommendations on continuous glucose monitoring.Chawla M, Saboo B, Jha S, Bhandari S, Kumar P, Kesavadev J, Munjal YP, Mohan V, Unnikrishnan R, Katswar V, Arun N, Sosale B, Anjana RM, Hasnani D. J Diabetol. Nov 2019. 10. 4-14. Read More
54. Consensus Statement on Use of Ambulatory Glucose Profile in Patients with Type 2 Diabetes Mellitus Receiving Oral Antidiabetic Drugs.Unnikrishnan AG, Saboo B, Joshi S, Kesavadev J, Makkar BM, Agarwal S, Aravind SR, Seshadri K, Chawla M, Deshpande N, Chawla R, Tiwaskar M. J Assoc Physicians India.Nov 2019. 67(11). 76-83. Read More
53. Inertia for the Use of Technological Advances for Effective Diabetes Management.Kesavadev J. Int J Diab Sep 2019.1-2. Editorial. Read More
52. Recommendations for in-clinic PoCT for diabetes management in India.Saboo B, Sadikot S, Prasanna Kumar KM, Joshi S, Aravind SR, Makkar BM, Chawla R, Kesavadev J, Chawla M, Kovil R, Shah T, Mohit M, Vyas C, Dhandhania VK. Diabetes Metab Syndr. Jan-Feb 2019. 13(1). 5-7. Read More
51. Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus.Kalra S, Kesavadev J,Chadha M, Kumar G. V. Indian J Endocrinol Metab. Nov 2018. 22(6). 827–836. Read More
50. The JADE Collaborative Study Group. Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program.Gani L, Lau E, Luk A, Sobrepena L, Tran Q. K, Kesavadev J, Jia W, Yu W, Tsang C. C, Mukhopadhyay M, Jha S, Sheu W, Ho Y. K, Nguyen T. N, Ozaki R, So W. Y, Kwan C, Fu A. W. C, Mirasol R, Phatak S. R, Kumar K. M. P, Aravind S, Janakiraman H, Chan J. C. N. J Diabetes Investig. Oct 2018. 9(6). 1312–1322. Link 1 | Link 2
49. Exploratory CSII Randomized Controlled Trial on Erectile Dysfunction in T2DM Patients (ECSIITED).Kesavadev J, Pillai P. B. S, Shankar A, Warrier R. S, Ramachandran L, Jothydev S, Krishnan G. J Diabetes Sci Technol. Aug 2018. 12(6). 1252–1253. Read More
48. Use of Ambulatory Glucose Profile for Improving Monitoring and Management of T2DM. Saboo B, Sheth SV, Joshi S, Bhandari S, Kesavadev J, Maheshwari A, Agrawal M, Hasnani D, Patel F, Panchal D, Goklani R. J Assoc Physicians India. Jul 2018. 66(7).69-71. Read More
47. JADE Collaborative Study Group. Cross-sectional survey of biosimilar insulin utilization in Asia: The Joint Asia Diabetes Evaluation Program.Gani L, Lau E, Luk A, Sobrepena L, Tran Q.K, Kesavadev J, Jia W, Yu W, Tsang C.C, Mukhopadhyay M, Jha S, Sheu W, Ho Y.K, Nguyen T.K, Ozaki R, So W.Y, Kwan C, Fu A.W.C, Mirasol R, Phatak S.R, Kumar K.M.P, Aravind S, Janakiraman H, Chan J.C.N. J Diabetes Investig. 2018 Nov;9(6):1312-1322. PMID: 29575724; PMCID: PMC6215931. Read More
46. Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges.Kesavadev J, Shankar A, Ashok A.D, Srinivas S, Ajai N. A, Sanal G, Krishnan G, Ramachandran L, Jothydev S. J Diabetes Sci Technol. Jan 2018. 12(1). 230–231. Read More
45. Evidence-based recommendations for insulin intensification strategies after basal insulin in type 2 diabetes.Ghosh S, Unnikrishnan A. G, Saboo B, Kesavadev J, Aravind S. R, Bajaj S, Rajput R, Seshadri K, Verma N, Gupta A, Makkar B. M, Saikia M, Kale S, Damodaran S, Dengra A, Eashwar T. K. M, Maheshwari A, Pendsey S, Phatak S. R, Sharma S. K, Singh S. K, Ramachandran A, Zargar A. H, Joshi S. R, Sadikot S. M. Diabetes Metab Syndr. Nov 2017. 11(S1). S507-S521. Read More
44. Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM).Kesavadev J, Pillai P. B. S, Shankar A, Krishnan G, Jothydev S. Endocr Connect. Nov 2017. 6(8). 748–757. Read More
43. A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes.Anjana R. M, Kesavadev J, Neeta D, Tiwaskar M, Pradeepa R, Jebarani S, Thangamani S, Sastry N. G, Kumar B. S, Ramu M, Gupta P. P. K, Vignesh J, Chandru S, Kayalvizhi S, Jagdish P. S, Uthra S. C. B, Lovelena M, Jyoti S, Priya S. S, Kannan A, Mohan V, Unnikrishnan R. Diabetes Technol Ther. Sep 2017. 19(9). 533-540. Read More
42. Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation.Kesavadev J, Vigersky R, Shin J, Pillai P. B. S, Shankar A, Sanal G, Krishnan G, Jothydev S. Adv Ther. Aug 2017. 34(8). 1918-1927. Read More
41. Liraglutide and Renal Outcomes in Type 2 Diabetes.Mann J. F. E , Ørsted D. D , Frandsen K. B, Marso S. P, Poulter N.R, Rasmussen S , Tornøe K, Zinman B , Buse J. B , LEADER Steering Committee and Investigators. N Engl J Med. Aug 2017 31;377 (9):839-848. Link 1 | Link 2
40. Forum for Injection Technique and Therapy Expert Recommendations, India: The Indian Recommendations for Best Practice in Insulin Injection Technique, 2017.Tandon N, Kalra S, Balhara Y. P. S, Baruah M. P, Chadha M, Chandalia H. M, Kumar K. M. P, Madhu S. V, Mithal A, Sahay R, Shukla R, Sundaram A, Unnikrishnan A. G, Saboo B, Gupta V, Chowdhury S, Kesavadev J, Wangnoo S. K. Indian J Endocrinol Metab. Jul-Aug 2017. 21(4). 600–617. Read More
39. Clinical practice points for diabetes management during RAMADAN fast.Sadikot S. M, Jothydev K, Zargar A. H, Ahmad J, Arvind S. R, Saboo B. Diabetes Metab Syndr. Jun 2017. 11(S2). S811-S819. Read More
38. Consensus on Initiation and Intensification of Premix Insulin in Type 2 Diabetes Management.Mohan V, Kalra S, Kesavadev J, Singh A. K, Kumar A, Unnikrishnan A. G, Chawla R, Mukherjee J.J, Sahay R. K, Kumar J. S, Bhoraskar A, Asirvatham A. J, Panda J. K, Zargar A. H, Das A. K. J Assoc Physicians India. Apr 2017. 65(4). 59-73. Read More
37. Consensus recommendations on exploring effective solutions for the rising cost of diabetes.Sadikot S. M, Das A. K, Wilding J, Siyan A, Zargar A. H, Saboo B, Aravind S. R, Sosale B, Kalra S, Vijayakumar G, Manojan K. K, Maheshwari A, Panda J. K, Banerjee S, Chawla R, Vasudevan S. P, Sundar O. S. S, Kesavadev J. Diabetes Metab Syndr. Mar 2017. 11(2). 141-147. Link 1 | Link 2
36. Efficacy and safety concerns regarding Complementary and Alternative Medicine use among diabetes patients.Kesavadev J. J Pak Med Assoc. 2017. 67(2). 316-319. Read More
35. Consensus on Insulin Dose and Titration Algorithms in Ambulatory Care of Type 2 Diabetes in India.Kovil R, Chawla M, Rajput R, Singh A. K, Sinha B, Ghosal S, Ballani P, Gupta S, Tanna S, Bandukwala S. M, Shah T, Negalur V, Bhoraskar A, Aravind S. R, Zargar A. H, Kesavadev J, Das A. K. J Assoc Physicians India. Feb 2017. 65(2). 17-30. Read More
34. Glucose monitoring technologies - Complementary or competitive? Role of Continuous Glucose Monitoring versus flash glucose monitoring versus self-monitoring of blood glucose.Kesavadev J, Ramachandran L, Krishnan G. J Diabetol. Jan 2017. 8(3). 61-67. Review. Read More
33. Unproven Therapies for Diabetes and Their Implications.Kesavadev J, Saboo B, Sadikot S, Das A. K, Joshi S, Chawla R, Thacker H, Shankar A, Ramachandran L, Kalra S. Adv Ther. 2017. 34(1). 60-77. Read More
32. Platelet Proteins From Diabetic Subjects Cause Phenotypic Changes In Endothelial Cells In-Vitro.Hilary S, Shahna S, Kesavadev J ,Bhatt A. International Journal Of Life Science And Pharma Research. 2016. 7(1). 61-71. Read More
31. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.Marso S. P , Daniels G. H , Frandsen K. B , Kristensen P , Mann J. F. E , Nauck M. A , Nissen S. E , Pocock S , Poulter N. R , Ravn L. S , Steinberg W. M , Stockner M , Zinman B, Bergenstal R.M, Buse J. B , LEADER Steering Committee; LEADER Trial Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22. Link 1 | Link 2
30. Insulin pump therapy in pregnancy.Kesavadev J. J Pak Med Assoc. Sep 2016. 66(9S1). S39-44.Review. Read More
29. Use of Retrospective Continuous Glucose Monitoring for Optimizing Management of Type 2 Diabetes in India.Mohan V, Jain S, Kesavadev J, Chawla M, Mutha A, Viswanathan V, Saboo B, Kovil R, Mithal A, Punatar D, Shin J. J Assoc Physicians India. Apr 2016. 64(4). 16-21. Read More
28. CSII as an Alternative Therapeutic Strategy for Managing Type 2 Diabetes: Adding the Indian Experience to a Global Perspective.Kesavadev J, Shankar A, Pillai P. B. S, Saboo B, Joshi S, Krishnan G, Jothydev S. Curr Diabetes Rev. 2016. 12(4). 312-314. Read More
27. The two levels of care for diabetes in a developing country: Mechanisms for improved intermediate health outcomes.Vitale R. J, Pillai P. B, Krishnan G, Jothydev S, Kesavadev J. Diabetes Metab Syndr. Jan- Mar 2016. 10(1S1).S90-S94. Read More
26. Telemedicine for diabetes care: An Indian perspective - feasibility and efficacy.Kesavadev J, Saboo B, Shankar A, Krishnan G, Jothydev S. Indian J Endocrinol Metab. Nov- Dec 2015. 19(6). 764–769. Read More
25. Consensus Statement on Management of Post-Prandial Hyperglycemia in Clinical Practice in India.Aravind S, Saboo B, Sadikot S, Shah S.N, Makkar B, Kalra S, Kannampilly J, Kesavadev J, Ghoshal S, Zargar A, Nigam A, Hazra D, Tripathi K, Dharmalingam M, Shah P, Gandhi P, Sahay R, Unnikrishnan R, Gupta S, Bajaj S, Mukhopadhyay S, Kale S. J Assoc Physicians India. 2015 Aug;63(8):45-58. PMID: 27604435. Read More
24. Fasting in Ramadan with an insulin pump.Kesavadev J. J Pak Med Assoc. 2015. 65(5S1). S47-50. Read More
23. Forum for Injection Technique (FIT), India: The Indian recommendations 2.0, for best practice in Insulin Injection Technique, 2015.Tandon N, Kalra S, Balhara Y.P, Baruah M.P, Chadha M, Chandalia H.B, Chowdhury S,Kesavadev J, Kumar PK, V M.S, Mithal A, Modi S, Pitale S, Sahay R, Shukla R, Sundaram A, Unnikrishnan A.G, Wangnoo S.K. Indian J Endocrinol Metab. May-Jun 2015;19(3):317-31. PMID: 25932385; PMCID: PMC4366768. Read More
22. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S.Diabetes Metab Syndr. May 2015. 9(1). 30-33. Read More
21. Intensifying Insulin Therapy in Type 2 Diabetes: Choices & Challenges.Kumar A, Kesavadev J, Sethi B, Jain S. M, Guruprasad C. S, Shah S. N. J Assoc Physicians India. May 2015. 63(5S). 8-14. Review. Read More
20. Challenges in Type 1 diabetes management in South East Asia: Descriptive situational assessment.Kesavadev J, Sadikot S. M, Saboo B, Shrestha D, Jawad F, Azad K, Wijesuriya M. A, Latt T. S, Kalra S. Indian J Endocrinol Metab. Sep-Oct 2014. 18(5). 600–607. Read More
19. Consensus evidence-based guidelines for use of insulin pump therapy in the management of diabetes as per Indian clinical practice.Kesavadev J, Jain S.M, Muruganathan A, Das A.K; Diabetes Consensus Group. J Assoc Physicians India. Jul 2014 ;62(7 Suppl):34-41. Read More
18. Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM.Kesavadev J, Sadikot S. M, Wangnoo S, Kannampilly J, Saboo B, Aravind S. R, Kalra S, Makkar B. M, Maji D, Saikia M, Anjana R. M, Rajput R, Singh S. K, Shah S, Dhruv U, Vishwanathan V. Diabetes Metab Syndr. May 2014. 8(3). 187-195. Read More
17. Understanding the safety of the new ultra long acting basal insulin. Ramachandran A, Gupta V, Kesavadev J, Kalra S. J Assoc Physicians India. 2014 Jan;62(1 Suppl):35-42. PMID: 25330630. Read More
16. Addendum: First injection technique recommendations for patients with diabetes, Forum for Injection Techniques India.Kalra S, Balhara Y. P. S, Baruah M. P, Chadha M, Chandalia H. B, Chowdhury S, Kesavadev J, Kumar K. M. P, Modi S, Pitale S, Rishi S, Sahay R, Sundaram A, Unnikrishnan A. G, Wangnoo S. K. Indian J Endocrinol Metab. Nov-Dec 2013. 17(6). 1005–1008. Read More
15. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study.Kesavadev J. Indian J Endocrinol Metab. Nov 2013. 17(S2). S565–S568. Read More
14. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Diabetes, obesity and metabolism. 2013.15(8): 729-736. Read More
13. Barriers and solutions to diabetes management: An Indian perspective.Wangnoo S. K, Maji D, Das A. K, Rao P. V, Moses A, Sethi B, Unnikrishnan A. G, Kalra S, Bantwal V. B. G, Kesavadev J, Jain S. M, Dharmalingam M. Indian J Endocrinol Metab. Jul-Aug 2013. 17(4). 594–601. Read More
12. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study. Kesavadev J, Joshi S. R. J Assoc Physicians India. Jan 2013. 61(S1). 28-30. Read More
11. Suggested use of vaccines in diabetes.Kesavadev J, Misra A, Das A. K, Saboo B, Basu D, Thomas N, Joshi S. R, Unnikrishnan A. G, Shankar A, Krishnan G, Unnikrishnan R, Mohan V.Indian J Endocrinol Metab. Nov 2012. 16(6). 886–893. Read More
10. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus - a retrospective study.Kesavadev J, Shankar A, Pillai P. B. S, Krishnan G, Jothydev S. Diabetes Technol Ther. Sep 2012. 14(9). 772-776. Read More
9. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting.Kesavadev J, Shankar A, Krishnan G, Jothydev S. Int J Gen Med. Apr 2012. 5. 317-322. Read More
8. Geographical location and effectiveness of a simple telemedicine program (DTMS®) in diabetes.Kesavadev J, Pillai P. B. S, Shankar A, Gopalakrishnan G, Lally J, Jothydev S. Diabetes Technol Ther. 2012 Feb. 14(19). Read More
7. Acceptance of Continuous Glucose Monitoring (CGM) as a Routine Investigation in Diabetes.Kesavadev J, Pillai P. B. S, Shankar A, Gopalakrishnan G, Lally J, Sanal G, Jothydev S.Diabetes Technol Ther. Feb 2012. 14(19). Read More
6. An Asian Indian woman with Wolfram syndrome on insulin pump: successful pregnancy and beyond.Kesavadev J, Kumar A, Shankar A, Gopalakrishnan G, Permutt M. A, Wasson J, Jothydev S. Diabetes Technol Ther. Jul 2011. 13(7). 781-785. Read More
5. Continuous insulin infusion systems in type 2 diabetes.Kesavadev J. J Assoc Physicians India. 2011 Apr. 59(S). 41-43 Read More
4. A Clinician’s Perspective on Liraglutide in Clinical Practice. Tandon N, John M, Sharma S. K, Kesavadev J, Ganapathy B. J Assoc Physicians India, 2010. 58. 29-30. Read More
3. Use of Insulin Pumps in India: Suggested Guidelines Based on Experience and Cultural Differences. Kesavadev J, Das A.K, Unnikrishnan R, Joshi S. R, Ramachandran A, Shamsudeen J, Krishnan G, Jothydev S, Mohan V. Diabetes Technol Ther. 2010. 12(10). 823–831. Read More
2. Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Kesavadev J, Balakrishnan S, Ahammed S, Jothydev S. Diabetes Technol Ther. 2009. 11(8). 517-521. Read More
1. Diabetes in old age: an emerging epidemic. Kesavadev J, Short K.R, Nair K.S. J Assoc Physicians India. 2003 Nov;51:1083-94. Read More